CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma
Adding the immunotherapy nivolumab to first-line chemotherapy helped patients with advanced stomach and oesophageal adenocarcinoma live longer, especially when the tumour showed PD-L1, making chemo-immunotherapy the new standard.
Open-label phase 3 trial of 1,581 patients with untreated, HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma randomised to nivolumab plus chemotherapy (XELOX or FOLFOX) or chemotherapy alone (a third arm tested nivolumab plus ipilimumab). Primary endpoints were OS and PFS in patients with PD-L1 combined positive score (CPS) of 5 or more.
In CPS 5 or more, median OS was 14.4 vs 11.1 months (HR 0.71) and PFS 7.7 vs 6.0 months (HR 0.68); in all randomised patients OS was 13.8 vs 11.6 months (HR 0.80). It was the first immunotherapy to improve first-line survival in gastric cancer and it made PD-L1 CPS testing standard, though regulators disagreed about the CPS threshold for use.
- CPS 5 or more: median OS 14.4 vs 11.1 months, HR 0.71 (98.4% CI 0.59-0.86); median PFS 7.7 vs 6.0 months, HR 0.68.
- All randomised patients: median OS 13.8 vs 11.6 months, HR 0.80 (99.3% CI 0.68-0.94).
- Objective response in CPS 5 or more: 60% vs 45%.
- Exploratory analysis showed little benefit in CPS below 5, and the EMA restricted the label to CPS 5 or more while the FDA initially approved it regardless of PD-L1 (later narrowed to CPS 1 or more).
- Grade 3-4 treatment-related adverse events 59% vs 44%.
Patients with newly diagnosed advanced stomach or oesophageal adenocarcinoma whose tumour is HER2-negative and PD-L1 positive (CPS 5 or more, or at least 1 in some regions) should receive chemotherapy with nivolumab (or pembrolizumab, from KEYNOTE-859), which adds about three months of median survival and doubles the chance of being alive at three years. The benefit in PD-L1-negative tumours is doubtful, and these patients may be better served by chemotherapy alone or by trials.
- Benefit is concentrated in PD-L1-positive tumours; the ITT result is driven by the CPS 5 or more subgroup.
- Open-label design; CPS scoring reproducibility is imperfect.
- Microsatellite-instability-high tumours (about 3%) derived very large benefit and inflate pooled estimates.
- The nivolumab plus ipilimumab chemotherapy-free arm failed to improve OS.
Pages like this
not linked directly; found by shared links- Key paperKEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation
Shares Lines of therapy, Platinum agents, PD-L1, Overall survival (OS).
- Key paperKEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer
Shares Lines of therapy, Combined positive score (CPS), Platinum agents, Overall survival (OS).
- Key paperRUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer
Shares Lines of therapy, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Overall survival (OS), Progression-free survival (PFS).
- TrialCheckMate 649
Shares Yelena Y. Janjigian, Combined positive score (CPS), PD-L1, Nivolumab.
- Key paperRELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma
Shares Lines of therapy, Bristol Myers Squibb, Overall survival (OS), Progression-free survival (PFS).
- Key paperCheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma
Shares Ipilimumab, Bristol Myers Squibb, Overall survival (OS), Memorial Sloan Kettering Cancer Center.
- Key paperPACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer
Shares Platinum agents, PD-L1, Overall survival (OS), Progression-free survival (PFS).
- Key paperKEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer
Shares Lines of therapy, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Overall survival (OS), Progression-free survival (PFS).